sales@reportocean.com (Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
Erythropoietin Drugs Market by Product Types (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa) and Applications (Anemia, Kidney Disorders, Neural Disease and Wound healing) - Global Opportunity Analysis and Industry Forecast, 2013 - 2020

Erythropoietin Drugs Market by Product Types (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa) and...

Home / Categories / Healthcare
Erythropoietin Drugs Market by Product Types (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa) and Applications (Anemia, Kidney Disorders, Neural Disease and Wound healing) - Global Opportunity Analysis and Industry Forecast, 2013 - 2020
Erythropoietin Drugs Market by Product...
Report Code
RO1/113/1001

Publish Date
25/Nov/2024

Pages
115
PRICE
$ 4999/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 6004/-
This is a 1-5 user license, allowing up to five users have access to the product. The product is a PDF.
$ 8373/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..
TABLE 1 GLOBAL ERYTHROPOIETIN MODERATE GROWTH SCENARIO BY GEOGRAPHY, 2020-2025 ($MILLION)
TABLE 2 GLOBAL ERYTHROPOIETIN RAPID GROWTH SCENARIO BY GEOGRAPHY, 2020-2025 ($MILLION)
TABLE 3 GLOBAL ERYTHROPOIETIN DIMINISHING GROWTH SCENARIO BY GEOGRAPHY, 2020-2025 ($MILLION)
TABLE 4 ERYTHROPOIETIN DRUGS (COMPANIES, BRAND NAME, AND VARIANTS)
TABLE 5 CLINICAL TRIALS OF ERYTHROPOEITIN FOR NEURAL DISEASES AND WOUND HEALING
TABLE 6 COMPETITIVE INTELLIGENCE ON TOP THREE LEADERS IN ERYTHROPOIETIN MARKET
TABLE 7 BIOSIMILAR VERSION OF ERYTHROPOIETIN COMMERCIALIZED AND UNDER DEVELOPMENT
TABLE 8 CMS REIMBURSEMENT CODES FOR ERYTHROPOIETIN
TABLE 9 ORIGINATOR EPOTIN ALFA PRODUCTS AND THEIR REVENUES IN 2013
TABLE 10 BIOSIMILARS OF EPOETIN ALFA: APPROVED OR IN DEVELOPMENT PHASE
TABLE 11 CLINICAL TRIALS OF EPOETIN ALFA
TABLE 12 CMS POLICY CODES FOR EPOETIN ALFA
TABLE 13 EPOTIN BETA PRODUCTS AND THEIR REVENUES (2013)
TABLE 14 CLINICAL TRIALS FOR EPOETIN BETA
TABLE 15 CMS POLICY CODES FOR EPOETIN BETA
TABLE 16 BIOSIMILARS OF DARBEPOETIN ALFA
TABLE 17 CLINICAL TRIALS FOR DARBEPOETIN ALFA
TABLE 18 CMS POLICY CODES FOR DARBEPOETIN ALFA
TABLE 19 GLOBAL CANCER AND HIV INDUCED ANEMIA ERYTHROPOIETIN DRUGS APPLICATION MARKET BY GEOGRAPHY, 2013-2020, $MILLION
TABLE 20 DIALYSIS POPULATION GROWTH RATE IN 2013
TABLE 21 ESTIMATED (ESRD PATIENT) POPULATION BASE TAKING EPO THERAPY, 2013-2020, (THOUSAND)
TABLE 22 GLOBAL ESRD AND DIALYSIS INDUCED ANEMIA ERYTHROPOIETIN DRUGS APPLICATION MARKET BY GEOGRAPHY, 2013-2020, $MILLION
TABLE 23 GLOBAL NEURAL DISEASES AND WOUND HEALING INDUCED ANEMIA ERYTHROPOIETIN DRUG APPLICATION MARKET BY GEOGRAPHY, 2013-2020, $MILLION
TABLE 24 GLOBAL ERYTHROPOETIN MARKET BY GEOGRAPHY, 2013 - 2020 ($MILLION)
TABLE 25 SYNTHETIC ERYTHROPOIETIN MARKETED IN UNITED STATES
TABLE 26 REVISED USFDA GUIDELINES FOR THE DOSING OF ERYTHROPOIETIN STIMULATING AGENTS
TABLE 27 CMS POLICY DECISIONS FOR THE REIMBURSEMENT OF ERYTHROPOIETIN STIMULATING AGENTS
TABLE 28 NORTH AMERICA ERYTHROPOETIN MARKET BY PRODUCT TYPES, 2013 - 2020 ($MILLION)
TABLE 29 EMA APPROVED ERYTHROPOIETIN (BIOSIMILARS AND INNOVATOR PRODUCTS) IN EUROPE
TABLE 30 EUROPE ERYTHROPOETIN MARKET BY PRODUCT TYPES, 2013 - 2020 ($MILLION)
TABLE 31 BIOSIMILARS MARKETED IN ASIA-PACIFIC
TABLE 32 ASIA-PACIFIC ERYTHROPOETIN MARKET BY PRODUCT TYPES, 2013 - 2020 ($MILLION)
TABLE 33 LAMEA ERYTHROPOETIN MARKET BY PRODUCT TYPES, 2013 - 2020 ($MILLION)
TABLE 34 AMGEN INC. SNAPSHOT
TABLE 35 AMGEN INC. OPERATING BUSINESS SEGMENT
TABLE 36 JOHNSON & JOHNSON SNAPSHOT
TABLE 37 JOHNSON AND JOHNSON OPERATING SEGEMENTS
TABLE 38 ROCHE SNAPSHOT
TABLE 39 ROCHE OPERATING SEGEMENTS
TABLE 40 HOSPIRA SNAPSHOT
TABLE 41 HOSPIRA OPERATING SEGEMENTS
TABLE 42 LG LIFE SCIENCES LTD. DIAGNOSTICS SNAPSHOT
TABLE 43 LG LIFE SCIENCES LTD. DIAGNOSTICS OPERATING SEGEMENTS
TABLE 44 BIOCON SNAPSHOT
TABLE 45 BIOCON OPERATING SEGEMENTS
TABLE 46 INTAS PHARMACEUTICALS SNAPSHOT
TABLE 47 INTAS PHARMACEUTICALS OPERATING SEGEMENTS
TABLE 48 TEVA PHARMACEUTICAL INDUSTRIES LTD. SNAPSHOT
TABLE 49 TEVA PHARMACEUTICAL INDUSTRIES LTD. OPERATING SEGEMENTS
TABLE 50 RANBAXY LABORATORIES LTD. SNAPSHOT
TABLE 51 RANBAXY LABORATORIES LTD. OPERATING SEGEMENTS
TABLE 52 CELLTRION, INC. SNAPSHOT
TABLE 53 CELLTRION, INC. OPERATING SEGEMENTS
LIST OF FIGURE
FIG. 1 IMPACT ANALYSIS OF GLOBAL ERYTHROPOIETIN MARKET IN MODERATE GROWTH SCENARIO
FIG. 2 IMPACT ANALYSIS OF GLOBAL ERYTHROPOIETIN MARKET IN RAPID GROWTH SCENARIO
FIG. 3 IMPACT ANALYSIS OF GLOBAL ERYTHROPOIETIN MARKET IN DIMINISHING GROWTH SCENARIO
FIG. 4 GLOBAL ERYTHROPOIETIN (EPO) DRUGS MARKET DEFINITION
FIG. 5 EVOLUTION OF ERYTHROPOIETIN DRUGS
FIG. 6 TOP IMPACTING FACTORS OF GLOBAL ERYTHROPOIETIN DRUGS MARKET (2013-2020)
FIG. 7 TOP INVESTMENT POCKETS FOR GLOBAL ERYTHROPOIETIN DRUGS MARKET
FIG. 8 ERYTHROPOIETIN (EPO) VALUE CHAIN BY APPLICATION
FIG. 9 MARKET PLAYER POSITIONING OF ERYTHROPOIETIN DRUGS MARKET, 2014, (MILLION)
FIG. 10 ERYTHROPOIETIN PATENTED PRODUCT POSITIONING (2014)
FIG. 11 MARKET SHARE ANALYSIS OF GLOBAL ERYTHROPOIETIN DRUGS MARKET (2013)
FIG. 12 REGIONAL SALES OF NEORECORMON AND MIRCERA IN 2013 ($ MILLION)
FIG. 13 FORECAST ADOPTION OF EPO THERAPY BY GEOGRAPHY, 2013-2020 (% RATE)
FIG. 14 FINANCIAL REVENUE OF AMGEN INC. BY GEOGRAPHY (2013)
FIG. 15 FINANCIAL REVENUE OF AMGEN INC. BY PRODUCT PORTFOLIO (2013)
FIG. 16 SWOT ANALYSIS OF AMGEN INC.
FIG. 17 FINANCIAL REVENUE OF JOHNSON & JOHNSON BY GEOGRAPHY (2013)
FIG. 18 FINANCIAL REVENUE OF JOHNSON & JOHNSON BY BUSINESS UNITS (2013)
FIG. 19 SWOT ANALYSIS OF JOHNSON & JOHNSON
FIG. 20 FINANCIAL REVENUE OF ROCHE DIAGNOSTICS BY GEOGRAPHY (2013)
FIG. 21 FINANCIAL REVENUE OF ROCHE DIAGNOSTICS BY BUSINESS UNITS (2013)
FIG. 22 SWOT ANALYSIS OF ROCHE DIAGNOSTICS
FIG. 23 FINANCIAL REVENUE OF ROCHE DIAGNOSTICS BY GEOGRAPHY (2013)
FIG. 24 FINANCIAL REVENUE OF ROCHE DIAGNOSTICS BY BUSINESS UNITS (2013)
FIG. 25 SWOT ANALYSIS OF ROCHE
FIG. 26 SWOT ANALYSIS OF LG LIFE SCIENCES LTD.
FIG. 27 SWOT ANALYSIS OF HOSPIRA
FIG. 28 SWOT ANALYSIS OF INTAS PHARMACEUTICALS
FIG. 29 SWOT ANALYSIS OF TEVA PHARMACEUTICAL INDUSTRIES LTD.
FIG. 30 SWOT ANALYSIS OF RANBAXY LABORATORIES LTD.
FIG. 31 SWOT ANALYSIS OF CELLTRION, INC.

OUR CLIENTS

500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
+18882123539
sales@reportocean.com